Back in 2017, we wrote about a topic that vexes insurers and self-insured employers: specialty drugs. More specifically, we wondered whether specialty drugs are worth their high cost. Five years later, there aren’t any more conclusive answers about whether these drugs are effective enough to warrant sky-high prices—and in the ensuing five years, those prices have only gotten higher. Continue Reading >

Recent Comments